An AI-designed universal Sarbecovirus vaccine was found to be safe with no significant side effects in its first human clinical trial [1, 2].
This development marks a critical shift in pandemic preparedness. By creating a broadly protective vaccine, researchers aim to guard against future coronavirus threats before they trigger global outbreaks [1, 2].
The trial was conducted at University Hospital Southampton in the United Kingdom [3, 4]. It was led by researchers from the University of Cambridge and its spin-out company, DIOSynVax (DVX) Ltd [1, 2].
According to reports released June 9 and 10, the vaccine's key component was designed entirely by artificial intelligence [3, 4]. This AI-driven approach allows scientists to target conserved regions of the virus that do not mutate as quickly as the spike proteins targeted by earlier vaccines [1].
The primary goal of the research is to move beyond the reactive nature of vaccine development. Instead of creating new shots for every single variant, a universal vaccine would provide a baseline of protection across the entire Sarbecovirus lineage [1, 2].
Medical teams monitored the participants for adverse reactions during the study. The results indicated that the vaccine was safe and did not produce any significant side effects [1]. The researchers said they are now looking toward subsequent phases of testing to determine the level of immune response, and long-term efficacy [1, 2].
“The vaccine was safe with no significant side effects in the first human trial”
The successful first-in-human trial validates the use of AI to design complex biological components that can target multiple viral strains. If subsequent trials prove efficacy, this approach could eliminate the need for frequent booster updates and provide a rapid-response blueprint for preventing future zoonotic spillovers from becoming pandemics.
